Li Jiang1, Pengfei Li1, Qi Quan1, Ping Chen1, Huijuan Qiu1, Bei Zhang2. 1. Department of VIP Region, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 2. Department of VIP Region, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: zhangbeisysucc@163.com.
Abstract
BACKGROUND: The skin is the common extranasal sites in extranodal natural killer (NK) / T - cell lymphoma, (ENKTL). However, data regarding cutaneous ENKTL are relatively scarce. Thus, we performed a large retrospective study to analyze clinical features and treatment outcomes of cutaneous ENKTL. PATIENTS AND METHODS: Seventy-one patients with cutaneous ENKTL newly diagnosed between 2001 and 2018 were retrospectively analyzed from Sun Yat-sen cancer center. RESULTS: The median overall survival (OS) was 15.5 months (95 % confidence interval: 8.0-22.1 months). Age, treatment strategy, and treatment response were independent prognostic factors for cutaneous ENKTL. Patients who could undergo chemotherapy followed by radiotherapy showed a significantly better survival than those treated with chemotherapy alone (p < 0.001). The 3 - year OS rates were 73.9 % for patients who achieved complete response (CR) compared with 10.3 % for patients who did not (p < 0.001). CONCLUSION: We reported by far the largest series of cutaneous ENKTL, and demonstrated its aggressive clinical behavior and unsatisfying response to the current therapeutic strategies. Further investigations are required for the better understanding and management of this uncommon disease.
BACKGROUND: The skin is the common extranasal sites in extranodal natural killer (NK) / T - cell lymphoma, (ENKTL). However, data regarding cutaneous ENKTL are relatively scarce. Thus, we performed a large retrospective study to analyze clinical features and treatment outcomes of cutaneous ENKTL. PATIENTS AND METHODS: Seventy-one patients with cutaneous ENKTL newly diagnosed between 2001 and 2018 were retrospectively analyzed from Sun Yat-sen cancer center. RESULTS: The median overall survival (OS) was 15.5 months (95 % confidence interval: 8.0-22.1 months). Age, treatment strategy, and treatment response were independent prognostic factors for cutaneous ENKTL. Patients who could undergo chemotherapy followed by radiotherapy showed a significantly better survival than those treated with chemotherapy alone (p < 0.001). The 3 - year OS rates were 73.9 % for patients who achieved complete response (CR) compared with 10.3 % for patients who did not (p < 0.001). CONCLUSION: We reported by far the largest series of cutaneous ENKTL, and demonstrated its aggressive clinical behavior and unsatisfying response to the current therapeutic strategies. Further investigations are required for the better understanding and management of this uncommon disease.